Literature DB >> 25546779

Will sialylation change intravenous immunoglobulin therapy in the future?

F Käsermann1, I K Campbell.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 25546779      PMCID： PMC4285508          DOI： 10.1111/cei.12528

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  9 in total

1.  Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.

Authors:  Yoshikatsu Kaneko; Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2006-08-04       Impact factor: 47.728

2.  Identification of a receptor required for the anti-inflammatory activity of IVIG.

Authors:  Robert M Anthony; Fredrik Wermeling; Mikael C I Karlsson; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-26       Impact factor: 11.205

3.  Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

Authors:  Robert M Anthony; Falk Nimmerjahn; David J Ashline; Vernon N Reinhold; James C Paulson; Jeffrey V Ravetch
Journal:  Science       Date:  2008-04-18       Impact factor: 47.728

4.  Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils.

Authors:  Ian K Campbell; Sylvia Miescher; Donald R Branch; Patrick J Mott; Alan H Lazarus; Dongji Han; Eugene Maraskovsky; Adrian W Zuercher; Anton Neschadim; Danila Leontyev; Brent S McKenzie; Fabian Käsermann
Journal:  J Immunol       Date:  2014-04-23       Impact factor: 5.422

5.  Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin.

Authors:  Shivashankar Othy; Selma Topçu; Chaitrali Saha; Prathap Kothapalli; Sebastien Lacroix-Desmazes; Fabian Käsermann; Sylvia Miescher; Jagadeesh Bayry; Srini V Kaveri
Journal:  Eur J Immunol       Date:  2014-05-02       Impact factor: 5.532

6.  Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway.

Authors:  Robert M Anthony; Toshihiko Kobayashi; Fredrik Wermeling; Jeffrey V Ravetch
Journal:  Nature       Date:  2011-06-19       Impact factor: 49.962

7.  Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.

Authors:  Danila Leontyev; Yulia Katsman; Xue-Zhong Ma; Sylvia Miescher; Fabian Käsermann; Donald R Branch
Journal:  Transfusion       Date:  2012-01-18       Impact factor: 3.157

8.  Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation.

Authors:  Fabian Käsermann; David J Boerema; Monika Rüegsegger; Andreas Hofmann; Sandra Wymann; Adrian W Zuercher; Sylvia Miescher
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

9.  Contrasting mechanisms of interferon-α inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll-like receptor agonists.

Authors:  Alice E Wiedeman; Deanna M Santer; Wei Yan; Sylvia Miescher; Fabian Käsermann; Keith B Elkon
Journal:  Arthritis Rheum       Date:  2013-10
  9 in total
  1 in total

1.  Hidden IgG Antibodies to the Tumor-Associated Thomsen-Friedenreich Antigen in Gastric Cancer Patients: Lectin Reactivity, Avidity, and Clinical Relevance.

Authors:  Oleg Kurtenkov; Kersti Klaamas
Journal:  Biomed Res Int       Date:  2017-02-21       Impact factor: 3.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.